Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
164
Recruiting, any sponsor type, condition "major depressive disorder"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting164
- Completed1,159
164 trials
Showing 1 to 25, recently updated first.
Stony Brook UniversityAcademic, hospital or other
NCT04814355 · 50 participants (planned) · Start Aug 1, 2018 · Primary completion Aug 31, 2028
Drug: Celecoxib 400 mg · For: Major Depressive Disorder; Neuroinflammation
Sites: Stony Brook, New York
- A Study of Brenipatide in Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07928245 · 330 participants (planned) · Start Nov 10, 2026 · Primary completion May 2028
Drug: Brenipatide; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Fountain Valley, California; Montclair, California · 76 sites in all
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPivotal-lookingRecruiting
National Institute of Mental Health (NIMH)NIH
NCT00018057 · 3,500 participants (planned) · Start Oct 2, 2001 · Primary completion Jan 1, 2029
Drug: Fluoxetine · For: Anxiety Disorders; Major Depressive Disorder
Sites: Bethesda, Maryland; College Park, Maryland
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963021 · 200 participants (planned) · Start May 30, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Los Angeles, California; Stanford, California · 39 sites in all
- Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06786624 · 200 participants (planned) · Start Jan 22, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Garden Grove, California; Orange, California · 30 sites in all
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06911112 · 200 participants (planned) · Start Mar 31, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Cerritos, California · 42 sites in all
- A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07772531 · 200 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 6, 2028
Drug: BMS-986511; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 24 sites in all
- Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in HumansRecruiting
Deepak C. D'SouzaAcademic, hospital or other
NCT06671977 · 60 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 1, 2027
Drug: DMT-Medium Dose; DMT-Low Dose and 2 more · For: Major Depression Disorder; Depression
Sites: West Haven, Connecticut
Yale UniversityAcademic, hospital or other
NCT04711915 · 10 participants (planned) · Start Mar 17, 2021 · Primary completion Jul 1, 2030
Drug: 0.1 mg/kg Dimethyltryptamine (DMT); 0.3 mg/kg Dimethyltryptamine (DMT) · For: Major Depressive Disorder; Depression
Sites: West Haven, Connecticut
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07901179 · 180 participants (planned) · Start Nov 9, 2026 · Primary completion Jan 2028
Drug: ALKS 7290 Dose; Placebo · For: Major Depressive Disorder (MDD)
Sites: Jacksonville, Florida; North Canton, Ohio
National Institute of Mental Health (NIMH)NIH
NCT03973268 · 70 participants (planned) · Start Jan 21, 2020 · Primary completion Feb 1, 2027
Drug: Arm 1, 2, 3 drug Interventions; Arm 1 and 2 Interventions · For: Depression; Major Depressive Disorder; Major Depression
Sites: Bethesda, Maryland
Yale UniversityAcademic, hospital or other
NCT06442423 · 50 participants (planned) · Start Oct 17, 2024 · Primary completion Dec 2027
Drug: Psilocybin · For: Transdiagnostic; Depression - Major Depressive Disorder; Anxiety and 5 more
Sites: New Haven, Connecticut
- Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT07226661 · 230 participants (planned) · Start Jan 19, 2026 · Primary completion Dec 31, 2026
Drug: SPN-821 2400 mg; Placebo · For: Major Depressive Disorder (MDD)
Sites: Birmingham, Alabama; Phoenix, Arizona; Rogers, Arkansas · 40 sites in all
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPivotal-lookingRecruiting
Cybin IRL LimitedIndustry
NCT06793397 · 330 participants (planned) · Start Dec 10, 2025 · Primary completion Jun 7, 2027
Drug: CYB003 · For: Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder and 3 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 79 sites in all
- Precision Depression Adalimumab TrialRecruiting
Daniel MoriarityAcademic, hospital or other
NCT07845604 · 60 participants (planned) · Start Nov 2026 · Primary completion Jul 2031
Drug: Adalimumab Biosimilars Injection · For: Major Depressive Disorder (MDD)
Sites: Philadelphia, Pennsylvania
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)Pivotal-lookingRecruiting
Seaport TherapeuticsIndustry
NCT07065240 · 360 participants (planned) · Start Jun 19, 2025 · Primary completion Mar 2027
Drug: SPT-300; Placebo · For: Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
Sites: Chino, California; Garden Grove, California; Glendale, California · 62 sites in all
- The Role of mGluR5 in CBT-IRecruiting
Stony Brook UniversityAcademic, hospital or other
NCT07076342 · 42 participants (planned) · Start Aug 1, 2025 · Primary completion Mar 31, 2030
Drug: PET Scan with [11C]ABP688 · For: Major Depressive Disorder (MDD)
Sites: Stony Brook, New York
- Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)Pivotal-lookingRecruiting
University Hospital TuebingenAcademic, hospital or other
NCT06545474 · 106 participants (planned) · Start Sep 15, 2024 · Primary completion Jul 31, 2027
Drug: SSRI treatment · For: Major Depressive Disorder
Sites: Tübingen, Germany
Massachusetts General HospitalAcademic, hospital or other
NCT05450432 · 100 participants (planned) · Start Oct 13, 2022 · Primary completion May 1, 2027
Drug: Ketamine; Esketamine · For: Major Depressive Disorder
Sites: Boston, Massachusetts
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Pivotal-lookingRecruiting
Definium Therapeutics US, Inc.Industry
NCT07592689 · 165 participants (planned) · Start May 10, 2026 · Primary completion Sep 2027
Drug: DT120 · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Orange, California; San Diego, California · 26 sites in all
University of OxfordAcademic, hospital or other
NCT07848477 · 60 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 2028
Drug: Prucalopride; Placebo Comparator · For: Low Mood; Depression - Major Depressive Disorder
Sites: Oxford, United Kingdom
- Understanding and Treating Suicidal Ideation With KetaminePivotal-lookingRecruiting
The Royal's Institute of Mental Health ResearchAcademic, hospital or other
NCT06891300 · 36 participants (planned) · Start Apr 8, 2025 · Primary completion Mar 2027
Drug: ketamine hydrochloride · For: Suicidal Ideation; Major Depressive Disorder (MDD)
Sites: Ottawa, Canada
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPivotal-lookingRecruiting
National Institute of Mental Health (NIMH)NIH
NCT03065335 · 150 participants (planned) · Start May 25, 2017 · Primary completion Jan 1, 2027
Drug: Ketamine · For: Healthy Volunteer; Major Depressive Disorder; Depression
Sites: Bethesda, Maryland
- Behavioural Activation Therapy and Ketamine for Treatment-Resistant DepressionPivotal-lookingRecruiting
The Royal's Institute of Mental Health ResearchAcademic, hospital or other
NCT07801703 · 60 participants (planned) · Start Oct 30, 2026 · Primary completion Sep 2029
Drug: Ketamine (0.5 mg/kg) · For: Treatment Resistant Depression; Major Depressive Disorder (MDD)
Sites: Ottawa, Canada
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT07680140 · 27 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 2028
Drug: Ketamine · For: Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD); rTMS and 2 more
Sites: New York, New York · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.